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Keratin intermediate filaments play an important role in maintaining the integrity of
the skin structure. Understanding the importance of this subject is possible with the
investigation of keratin defects in epidermolysis bullosa simplex (EBS). Nowadays, in
addition to clinical criteria, new molecular diagnostic methods, such as next
generation sequencing, can help to distinguish the subgroups of EBS more precisely.
Because the most important and most commonly occurring molecular defects in these
patients are the defects of keratins 5 and 14 (KRT5 and KRT14), comprehending
the nature structure of these proteins and their involved processes can be very
effective in understanding the pathophysiology of this disease and providing new and
effective therapeutic platforms to treat it. Here, we summarized the various aspects
of the presence of KRT5 and KRT14 in the epidermis, their relation to the incidence
and severity of EBS phenotypes, and the processes with which these proteins can
affect them.
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1 | MOLECULAR ASPECTS OF KERATIN
The epidermis (superficial skin layer) has many important
physiological roles, including creation of a physical barrier against
the influence of external factors, setting a body temperature,
defensive performance, protection of the body and internal
organs against the destructive effects of sunlight (Segre, 2006).
In the human body, the formation of the epidermis from the
primary ectoderm begins in the first 4 months of pregnancy.
Then, in 28‐day periods, it is recreated by very regular processes.
In this period, keratinocytes, which are the majority of epidermal
cells, gradually differentiate into four consecutive cell layers.
These layers include a layer with proliferation power (called
stratum basale) and three differentiated cellular layers (called
stratum spinosum, stratum granulosum, and stratum corneum)
(Segre, 2006).
Given that the epidermis is the outer layer of the skin and is
constantly exposed to external (environmental) factors, the epidermis
should withstand various stresses, such as mechanical erosion and
temperature change (Pekny & Lane, 2007). All over the epithelial cell
cytoplasm, a uniform spatial network of filaments is created by
keratins. In fact, keratin, by attaching to a cell membrane at the site of
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desmosome junction and hemidesmosome junction to the nuclear
membrane, plays an important role in maintaining the integrity of the
epidermis. Hence, the ability to withstand environmental tensions and
stresses is due to keratinocytes (keratin producing cells; Godsel,
Hobbs, & Green, 2008).
Keratin is a member of the protein family of intermediate
filaments and is the most abundant protein in the epithelial cells
cytoplasm (Omary, Coulombe, & McLean, 2004). Structurally,
keratins have a central rod‐shaped alpha helix domain and two
nonhelix domains on both sides (tail and head). This structure is
common among all types of keratins. At the beginning and the end of
a central rod‐shaped region, there are two strongly conserved and
unchanged amino acid sequences, which are called initial and
terminal helices. In the formation of helix–helix heterodimer
structures in keratin molecules, these initial and terminal structures
play a very important role (Omary et al., 2004).
Keratins are divided into two categories: type I (acidic) and
type II (alkaline). They are organized in two gene clusters in
chromosomal positions 17q21.2 and 12q13.3, respectively (Omary
et al., 2004). The diversity observed in living cells is due to the
multiplicity of keratin genes as well as the plurality of polymeric
connections of keratins type I and II (Hatzfeld & Franke, 1985). The
differentiation of keratinocytes is determined by the expression
pattern of the keratin gene (highly regulated; Lane & McLean,
2004). The keratinocytes located on stratum basal mainly express
keratins 5 and 14 (KRT5 and KRT14; Langbein et al., 2005; Nelson
& Sun, 1983). KRT2 is expressed on the higher epidermis
suprabasal layers (Collin, Moll, Kubicka, Ouhayoun, & Franke,
1992). Among the keratins, some are expressed in a specific
anatomical region only. For example, KRT9 is expressed on the skin
of the hand palm and foot sole (Langbein, Heid, Moll, & Franke,
1993) and KRT6b and KRT17 are expressed in follicular epithelium
cells (Covello et al., 1998; Smith et al., 1998; Wojcik, Longley, &
Roop, 2001). In addition to specific anatomical expression, some
types of keratin are expressed in terms of specific conditions. For
example, KRT6a and KRT16 are expressed at the time of wound
healing (Rosenberg, RayChaudhury, Shows, Le Beau, & Fuchs,
1988; Wojcik, Bundman, & Roop, 2000). Keratins play an important
role in maintaining cellular structure and differentiated or
specialized normal cellular function in the epithelial layer
(Moll, Divo, & Langbein, 2008). These proteins are involved in
some of the nonstructural regulatory processes including
protein synthesis (Kim, Wong, & Coulombe, 2006), cell migration
(Tao, Berno, Cox, & Frazer, 2007), and apoptosis (Tong &
Coulombe, 2006).
2 | EPIDERMOLYSIS BULLOSA SIMPLEX
AND KERATINS
Epidermolysis bullosa simplex (EBS) is one of the most common
genetic bullous skin diseases. It is characterized by the separation of
the skin at the basal keratinocytes region after trauma and blister
formation (Fine et al., 2008). It is estimated that the incidence of this
disease is about one in every 25,000–50,000 people (Pfendner, Uitto,
& Fine, 2001).
It is worth noting that in Western countries (because of the low level
of consanguineous marriages), most people with EBS have an autosomal
dominant inheritance pattern. However, in countries with more
consanguineous marriages, such as Middle Eastern countries, the
autosomal recessive form is more common (Ciubotaru et al., 2003;
McKenna, Walsh, & Bingham, 1992; Sa’d et al., 2006). Based on the
region of blister formation in the epidermis, epidermolysis bullosa
disease is classified into four groups: intraepidermal (EBS/epidermolytic),
intralamina lucida (junctional EB), sublamina densa (dystrophic EB), and
Kindler syndrome (Intong & Murrell, 2012). EBS is known as a
heterogeneous group, which is divided into four most common subtypes
(Pfendner et al., 2016): localized EBS (also known as Weber–Cockayne
type), generalized intermediate EBS (also known as Koebner type), EBS
with mottled pigmentation, and generalized severe EBS (also known as
Dowling–Meara type). EBS based on site of cleavage is divided into two
groups: suprabasal EBS and basal EBS, which are classified in Table 1.
KRT5 and KRT14 gene mutations are responsible for approximately 75%
of cases with EBS (Bolling, Lemmink, Jansen, & Jonkman, 2011; Pfendner
et al., 2016). Heterozygous missense mutations in KRT5 and KRT14
genes are the most common cause of disease in people with EBS (Bolling
et al., 2011; Lane & McLean, 2004). However, as mentioned above, in
Western societies, because of low prevalence of consanguineous
marriages, a large number of patients with EBS have an autosomal
dominant inheritance pattern. However, with an increase in the
prevalence of consanguineous marriages, more recessive cases are seen.
For example, in the Middle East, about 30% of patients have recessive
mutations in KRT14 (Ciubotaru et al., 2003; Sa’d et al., 2006). The
phenotypes produced by KRT5 and KRT14 genes mutations are
classified in Table 2 with their clinical criteria.
Most of the KRT5 and KRT14 mutations affect these filaments in
the central alpha helix region. Disturbance in this part render these
keratin molecules incapable of tolerating even low levels of
mechanical pressure. Subsequently, the basal cellular layer is
exposed to cytolysis (Uitto, Richard, & McGrath, 2007).
The phenotype–genotype analysis of patients has shown that the
relationship between the mutations affect the preserved initial and
the terminal points of the central rod and the creation of a more
severe phenotype (EBS Dowling–Meara [EBS‐DM]). While mutations
affecting the less‐protected areas of keratin molecules are associated
with a milder phenotype (localized EBS) (Uitto & Richard, 2005; Uitto
& Richard, 2004; Liovic et al., 2001; however, this does not happen all
the times) (Ciubotaru et al., 2003; Sa’d et al., 2006). It should
be noted that in addition to the spatial location of the mutation, the
nature of the replaced amino acid also affects the severity of the
disease (Murrell, Trisnowati, Miyakis, & Paller, 2011; Sørensen
et al., 1999).
To treat EBS, the investigation of molecular pathology plays a
crucial role. Because most EBS‐induced mutations have a dominant
negative effect, the introduction of a natural allele to cell may not
affect the treatment patients with EBS. A more effective way to treat
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TABLE 2 The phenotypes created by KRT5 and KRT14 genes mutations
Types of EBS Clinical features Reference
Dowling–Meara type
(generalized severe)
• Common mutation: heterozygous missense K14
mutation R125C which affects the helix initiation
motif in the helix 1A
• The most severe form
• Onset age: commonly at birth
• Pervasive blistering occurring from birth
• Blisters occur in herpetiform clusters on the trunk
and proximal extremities
• Healing of blisters with minor scarring
• Nails dystrophy
• Milia
• Progressive hyperkeratosis of the palms and soles
• Hypopigmentation and hyperpigmentation
• Neonatal or infant death due to high severe
blistering
• Mucosal involvement: frequently
(Anton‐Lamprecht & Schnyder, 1982; Ishida‐Yamamoto
et al., 1991; McGrath et al., 1992; Pfendner et al.,




• Onset age: at Birth or early infancy
• Severity of Involvement: Intermediate EBS‐localized
and EBS‐generalized severe
• Mucosal and teeth involvement: may be mildly
involved
• Hyperkeratosis of the palms and soles occur
sometimes
• Hypopigmentation and hyperpigmentation, milia
maybe arise
(Pfendner et al., 2016)
Localized EBS (previously
EBS, Weber‐Cockayne)
• The mildest form
• Onset age: rarely at birth, usually at Infancy with
12–18 months age, occasionally in adolescence or
early adulthood
• Hyperkeratosis of the palms and soles occur
sometimes
• Blisters Typically restricted to hands and feet
• Mucosal involvement: Infrequent
• There is no trace of hypopigmentation and
hyperpigmentation
(Y. M. Chan et al., 1993; Pfendner et al., 2016)
Dowling‐Degos disease • Blistering is not observed
• Acantholysis is often seen
• Consequences of abnormality in transport of
melanosome and growth of epithelia are:
• Reticulate hyperpigmentation of the flexures
• Comedolike lesions on the neck
• Pitted perioral acneiform scars
(Betz et al., 2006; Jones & Grice, 1978; Sprecher
et al., 2007)
EBS with migratory circinate
erythema
• Common mutation: a frameshift mutation
(c.1649delG) disturbing the construction of tail
domain of keratin 5
• Vesicles incidence on the background of a migratory
circinate erythema
• Intraepidermal blister formation
• The lesions often heal with no scarring and brown
pigmentation(brown postinflammatory
hyperpigmentation)
(Castiglia et al., 2014; Choi & Kim, 2016; Gu et al., 2003)
EBS with mottled
pigmentation
• Common mutation: a missense mutation (p.P24L)
affecting KRT5 head domain
• Skin blistering
• Reticulate skin pigmentation
• Keratoderma
• Nail dystrophy
• Other mutations in KRT5 and KRT14 has been
reported that create same phenotype
(Browning & Mohr, 2012; Harel, Bergman, Indelman, &
Sprecher, 2006; Irvine et al., 2001; Uttam et al., 1996)
(Continues)
292 | KHANI ET AL.
EBS is to remove mutated keratin molecules (Smith et al., 2004; Cao,
Longley, Wang, & Roop, 2001).
The important point is that as the patient’s age increases, upon
increasing or compensating the expression of keratin genes with less
expression in the basal cell layer (such as KRT15) and reducing the
expression of mutated keratin genes, the patient phenotype is relatively
improves (Jonkman et al., 1996). The genetic background of people and
their ethnicity is also important in determining the genotype–phenotype
communicative aspects in different families and populations (Sa’d et al.,
2006). Revertant mosaicism has also been reported in one case with
EBS‐DM and another patient with Recessive EBS (revertant Mosaicism
of Keratin 14; Schuilenga‐Hut et al., 2002; Smith et al., 2004).
It should not be forgotten that the effect of nongenetic factors should
not be ignored. These nongenetic factors may affect the effectiveness
and incidence of sequence changes (genetic changes), for example, the
relationship manifestation of transient EBS‐like phenotype after treat-
ment by bexarotene in the presence of a silent polymorphism in KRT5
gene (Trufant et al., 2010).
3 | OTHER REGULATORY EFFECTS OF
KERATIN IN EBS
Structural fractures that occur in basal keratinocytes due to keratin
gene mutations are the cause of skin blistering in people with EBS (Ma,
Yamada, Wirtz, & Coulombe, 2001). However, phenotypic manifesta-
tions are not limited to the above‐mentioned mechanism. Other
mechanisms can be related to the disease phenotype. Some mutations
in the keratin gene affect the dynamism of cellular skeletons or
interfere with changes occurring after translation in natural keratin
(Coulombe & Omary, 2002; Werner et al., 2004).
Increase in apoptosis activity was also observed in these patients.
There is a strong possibilty that it is due to keratin aggregations and
upregulation of inflammatory responses in the pathogenesis of EBS (Lu
et al., 2007; Yoneda et al., 2004). One of the characteristics of EBS‐DM
is that the mutated keratin proteins that are badly polymerized are
accumulated in the cytoplasm. This affects cellular and tissue
pathophysiology. Therefore, the formation of a tissue and cellular stress
to respond to these cytoplasmic aggregations is not unlikely (D’Alessan-
dro, Russell, Morley, Davies, & Lane, 2002; Löffek et al., 2010).
A study on the gene expression analysis in a specific cell category of
EBS‐DM containing mutation in KRT14 gene indicated the upregulation
of the genes involved in controlling the development, apoptosis,
migration, epidermis and wound healing as a molecular result of
mutation in KRT14 (Wagner, Hintner, Bauer, & Onder, 2012).
A study on mouse transgenic models (Coulombe & Lee, 2012)
presents several new functions for the keratin proteins existing in the
skin epithelium, including the regulation of cell and tissue growth in
the epidermis and hair follicles (Reichelt & Magin, 2002; Tong &
Coulombe, 2006) and increasing keratinocytes proliferation
(Coulombe & Lee, 2012; DePianto, Kerns, Dlugosz, & Coulombe,
2010), which may be related to the incidence of EBS. The expression
of preinflammatory and/or mitogenic cytokines or chemokines
increases the proliferation of keratinocytes (DePianto et al., 2010).
4 | IMMUNOLOGICAL PERSPECTIVE OF
KERATINS IN EBS
Inflammation is one of the most important factors for the incidence
of pathologic complications of EBS. The mutation occurring in K5 and
K14, followed by changes in the structure of extracellular matrix
filaments, can increase the patient’s sensitivity to mechanical
stresses. Studies on k5−/− rats revealed that in the absence of
keratin filaments, the epidermis is completely separated from the
derma, resulting in severe symptoms (Cao et al., 2001; Peters, Kirfel,
Büssow, Vidal & Magin, 2001).
In addition to mechanical damages, which are the main cause of
EBS symptoms in patients with mutated keratin, other pathological
mechanisms can also play a role in promoting it. They include
preinflammatory cytokines and signaling pathways associated with
them (Lu et al., 2007; Yoneda et al., 2004).
The tumor necrosis factor (TNF) performs its function through
binding to its receptor at the target cells surface including TNFR1
and TNFR2. TNF binding to TNFR1 leads to the transfer of signals
through its cytoplasmic death domains via activating the proteins
adaptor, which converts procaspase 8 to active caspase 8. After this,
by activating proteases, the process of apoptosis occurs. In a study,
Yoneda et al. (2004) showed that TNF could lead to the death of
HaCaT keratinocyte cell line that was transiently transfected with
mutated K14 (K14Arg125Cys). This study indicated that these cells
release TNFα, which can lead to cell death via activating the TNFα
receptor in autocrine/paracrine pathways (Russell, Andrews, James,
& Lane, 2004).
IL1β is another preinflammatory cytokine that can play an
important role in EBS disease. This cytokine activates keratinocytes.
TABLE 2 (Continued)
Types of EBS Clinical features Reference
Autosomal recessive EBS • Cause: missense or nonsense mutations in KRT14





(Hovnanian et al., 1993; Sa’d et al., 2006)
Note. EBS: epidermolysis bullosa simplex; KRT5: keratin 5; KRT14: keratin 14.
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In basal keratinocytes, Interleukin‐1β is present in the cytoplasm in
the precursor form. After damage, it is processed and released. Like
TNF, as paracrine/autocrine, it leads to the change of gene
expression and ultimately the proliferation and migration of cells
(Freedberg, Tomic‐Canic, Komine, & Blumenberg, 2001).
One of the signaling pathways involved in EBS is the activation of
ERK and Akt due to mechanical stresses. The findings indicate that
the activation of this signaling pathway causes resistance to
apoptosis in keratinocyte cells with mutated keratin (Russell, Ross,
& Lane, 2010).
In addition, the activation of relevant transcription factors, such as
nuclear factor kappa-light-chain-enhancer of activated B cells (NF‐κB),
could provide the chemokines (i.e., CCL20, CCL19, and CCL2) which are
needed for a variety of biological processes, such as recruitment,
migration, and maturation of langerhans cells (Roth, Reuter, Wohlen-
berg, Bruckner‐Tuderman, & Magin, 2009). Langerhans cell, as
epithelium resident cells, present dendritic cells that can be produced
by of cytokines, and the expression of different molecules on their
surface plays an important role in stimulating or inhibiting the immune
system (Banchereau et al., 2012; Seneschal, Clark, Gehad, Baecher‐
Allan, & Kupper, 2012; Stoitzner, 2010). Various studies have shown
that langerhans cells can play a role in facilitating DNA destruction in
epithelial cells and squamous cell carcinoma (SCC) incidence. SCC is one
of the main causes of death in patients with EB (Montaudié, Chiaverini,
Sbidian, Charlesworth & Lacour, 2016).
5 | CONCLUSION
EBS is known as a heterogeneous group of genetic skin disorders, which
have many genetic reasons. Among these, the role of Keratins (KRT5 and
KRT14) is more powerful. KRT5 and KRT14 are the major keratins,
which are expressed in the basal epidermis. These proteins, according to
their own structure and as a member of the protein family of
intermediate filaments, play an important role in conserving the integrity
of the skin structure. To help patients with EBS and move on to a
practical treatment in the future for these patients, the exact recognition
of these proteins and the mechanisms involved is imperative.
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